September 26, 2019 Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
August 8, 2019 Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results
August 1, 2019 Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019
May 8, 2019 Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results
April 30, 2019 Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019
February 27, 2019 Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
February 19, 2019 Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019
January 3, 2019 Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored
November 21, 2018 Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
